RDHL Redhill Biopharma Ltd.

7.04
0  0%
Previous Close 7.04
Open
Price To Book 4.76
Market Cap 154,431,559
Shares 21,936,301
Volume 0
Short Ratio
Av. Daily Volume 56,442

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated 2H 2019.
RHB-204
Nontuberculous mycobacteria (NTM) infections
Phase 2a enrolment to be completed 2H 2019.
YELIVA
Cholangiocarcinoma
Phase 1/2 poster presentation at EORTC-NCI-AACR November 16, 2018.
YELIVA
Refractory or relapsed multiple myeloma - cancer
Phase 3 data released July 30, 2018. Primary endpoint met but further trial required.
RHB-104 MAP US
Crohn’s disease
NDA filing announced May 7, 2019.
RHB-105
H. pylori
Phase 3 top-line data released June 14, 2017 - primary endpoint met. Additional Phase 3 trial planned.
BEKINDA -GUARD
Gastroenteritis
Phase 2 top-line data released October 3, 2017 - primary endpoint met (borderline) - p=0.05. Follow up analysis identfied p value = 0.036. Phase 3 trial planned.
BEKINDA
IBS-D
Phase 2 initiated October 2016.
YELIVA
Hepatocellular carcinoma (HCC) - cancer

Latest News

  1. RedHill Biopharma Receives Allowance for New U.S. Patent Covering RHB-104 for Crohn’s Disease and RHB-204 for NTM Infections
  2. She left one Triangle public company to become CSO of another local public pharma
  3. RedHill Biopharma Appoints Dr. June Almenoff as Chief Scientific Officer
  4. RedHill Biopharma to Present at 2019 BIO International Convention
  5. RedHill Biopharma Expands Commercial Management Team Ahead of Planned Talicia® Launch
  6. RedHill Biopharma Reports First Quarter 2019 Financial Results and Operational Highlights
  7. RedHill Biopharma Submits New Drug Application for Talicia® for H. pylori Infection
  8. Israeli firms ramps up in Raleigh as drug nears approval
  9. RedHill Biopharma to Host First Quarter 2019 Financial Results Conference Call on May 7, 2019
  10. RedHill Biopharma to Present at Three Conferences in April
  11. RedHill Biopharma to Present at the BIO-Europe Spring 2019 Conference
  12. RedHill Biopharma to Present at the 31st Annual ROTH Conference
  13. RedHill Biopharma Announces New European and Japanese Patents for Talicia®
  14. RedHill Biopharma Provides Full-Year 2018 Financial Results and Operational Highlights
  15. RedHill Biopharma to Host Full-Year 2018 Financial Results Conference Call on February 26, 2019
  16. RedHill Biopharma Strengthens Management Team with Appointment of Rick D. Scruggs as Chief Operating Officer, U.S. Operations
  17. RedHill Biopharma to Present at the 8th Annual SVB Leerink Healthcare Conference
  18. RedHill Biopharma Announces Fifth U.S. Patent Covering TALICIA® for H. pylori Infection
  19. RedHill closes $20M public offering to prep commercialization of new drug
  20. RedHill Biopharma Announces Closing of $20 Million Underwritten Offering